A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA (Anti-C5) in Combination With EYLEA in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal Vasculopathy
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
At a glance
- Drugs Aflibercept (Primary) ; Avacincaptad pegol (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Adverse reactions
- Sponsors OphthoTech Corporation
- 11 Dec 2017 Status changed from planning to recruiting.
- 08 Nov 2017 Accordng to an OphthoTech Corporation media release, initial top-line data is expected to be available during the second half of 2019.
- 31 Jul 2017 New trial record